| | | | |
CUSIP No. 38942Q 202 | | SCHEDULE 13D | | Page 7 of 10 |
Reference is hereby made to the statements on Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2023, as amended by Amendment No 1 filed with the SEC on November 22, 2023 (collectively, the “Schedule 13D”) which is incorporated by reference.
This Amendment No. 2 to the Schedule 13D filed, relating to the common stock, par value $0.0001 per share (the “Common Stock”) of CalciMedica, Inc., a Delaware corporation (the “Issuer”) amends and supplements certain of the items set forth therein.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 is hereby amended supplemented by adding the following at the end of Item 3:
On January 19, 2024, Mr. Roberts and Ms. Leheny, among other investors, entered into a Securities Purchase Agreement (“Purchase Agreement”) with Issuer. Pursuant to the terms of the Purchase Agreement, Mr. Roberts and Ms. Leheny each acquired from Issuer 91,086 common shares at $4.2665 per share, 45,543 common share purchase warrants exercisable at $5.36 per share until December 31, 2024, and 45,543 common share purchase warrants exercisable at $7.15 per share until December 31, 2026. Mr. Roberts and Ms. Leheny each used personal funds to acquire the securities.
The Purchase Agreement and the resulting issuance of the securities thereunder was approved by an independent committee of the Issuer’s Board of Directors.
Item 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and supplemented as follows:
The Reporting Persons effected the following transactions in the Common Stock on the dates indicated, and such transactions are the only transactions in the Common Stock by the Reporting Persons in the sixty days preceding the filing of this Amendment, or since the last 13D filing, whichever is less:
| | | | | | | | | | | | | | |
Name
| | Nature of Transaction | | Date | | | Number of Shares of Common Stock | | | Price per Share | |
Leheny | | Acquired from Issuer | | | 1/23/2024 | | | | 91,086 | | | $ | 4.2665 | |
Roberts | | Acquired from Issuer | | | 2/5/2024 | | | | 91,086 | | | $ | 4.2665 | |
Item 7. Material to be Filed as Exhibits.